Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | GRM2 | Q14416 | 17/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1828147 | 0.82 | LMNA (0.61) | LMNAMAPTCYP2C9GRM2 | |
| SCHEMBL1828011 | 0.81 | LMNA (0.57) | LMNAMAPTCYP2C9GRM2 | |
| SCHEMBL27199572 | 0.81 | LMNA (0.64) | LMNAMAPTCYP2C9GRM2KDM4E | |
| SCHEMBL171728 | 0.81 | GRM2 (0.69) | LMNAMAPTCYP2C9GRM2 | |
| SCHEMBL4131086 | 0.80 | GRM2 (0.42) | GRM2KDM4EALDH1A1MAPK1 | |
| SCHEMBL27199458 | 0.80 | LMNA (0.59) | LMNAMAPTCYP2C9GRM2KDM4E | |
| SCHEMBL10460796 | 0.80 | LMNA (0.62) | LMNAMAPTCYP2C9GRM2KDM4E | |
| SCHEMBL16332029 | 0.77 | LMNA (0.59) | LMNAMAPTCYP2C9GRM2KDM4E | |
| SCHEMBL171630 | 0.76 | MAPT (0.55) | LMNAMAPTCYP2C9GRM2KDM4E | |
| Ricinine SCHEMBL257955 | 0.76 | MAPT (1.00) | LMNAMAPTCYP2C9GRM2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009032177-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | IDENIX PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060866-A1 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II | POLR2E, POLR2H, POLR2A | LMNA 3922/4885MAPT 4141/4885CYP2C9 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.